Based on evidence from clinical studies, gliflozins are currently being introduced into practice for heart failure with preserved ejection fraction (HFpEF) as early as hospitalization. Sharing experiences is therefore very valuable. Several symposia at the ESC 2022 congress focused on the issue of introducing these drugs into HF treatment, some of which also included illustrative case studies. For example, the case of a patient with HFpEF from the USA demonstrated the early initiation of empagliflozin during hospitalization.

Migraine is the most common type of primary headache. It affects about 10% of the world population. Recurring migraine attacks significantly reduce quality of life. Therefore, research in pharmacotherapy in recent years has logically focused on preventing attacks. The result is the latest possibility of biological treatment for migraines using monoclonal antibodies against CGRP receptors.

At the end of 2019, new recommendations were published by the American Society of Hematology (ASH) for the prevention of thromboembolic disease (VTE) in hospitalized patients. The new guidelines also addressed the duration of VTE prophylaxis in patients undergoing major surgical procedures.

Invasive fungal diseases are a significant cause of morbidity and mortality among immunocompromised pediatric patients with leukemia and post-hematopoietic stem cell transplantation. During the 8th European Conference on Infections in Leukemia (ECIL-8) in 2020, the pediatric group reviewed and updated recommendations for the diagnosis, prevention, and treatment of invasive fungal infections in pediatric patients.

The issue of nutrition, especially proteins, is a crucial aspect affecting the overall health and prognosis of critically ill patients. Two recent studies published in the journals Critical Care and Journal of Parenteral and Enteral Nutrition focused on nutrient intake.

The SPIRIT-H2H study compared the efficacy of ixekizumab and adalimumab, either as monotherapy or with concomitant methotrexate (MTX), in patients with psoriatic arthritis (PsA) who had not been previously treated with biologics. The results of the recent work presented below after one year of follow-up suggest that the efficacy of ixekizumab remains the same regardless of the use of MTX, while the efficacy of adalimumab increases in combination with MTX.

A recently published study by a team of authors from several American institutions focused on comparing the efficacy and safety of the 5th generation cephalosporin ceftaroline with the standard of care in the treatment of sepsis caused by methicillin-resistant Staphylococcus aureus (MRSA).

Prague, March 8, 2022 –⁠ Hundreds of thousands of patients in the Czech Republic can soon look forward to a treatment that may positively influence the progression of their disease. The European Medicines Agency (EMA) approved the registration of Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved left ventricular ejection fraction at the beginning of March. It thus becomes the first drug that doctors can prescribe to all patients, regardless of ejection fraction status. EMA had previously approved empagliflozin for the treatment of patients with chronic heart failure with reduced ejection fraction and for the treatment of adults with inadequately controlled type 2 diabetes. The drug was developed by Boehringer Ingelheim.

Moderate to severe atopic dermatitis (AD) often requires systemic therapy. The long-term safety of dupilumab in patients with this condition was evaluated in an open-label extension (OLE) of the LIBERTY AD study, the results of which were recently published.

To date, 45 cases of idiopathic (autoimmune) thrombocytopenic purpura (ITP) in individuals with confirmed SARS-CoV-2 infection have been published in the literature. In September 2020, a review summarizing the clinical profile and treatment outcomes of ITP in these individuals was released.

In the fight against antibiotic resistance, principles for the proper use of antibiotics (ATB) have been introduced globally. The following overview briefly describes the obstacles in leading rational antibiotic therapy and considers the use and benefits of biomarkers.

The following quiz has been prepared for you as an activity for relaxation and unwinding from today's hectic days. In an easy manner, it will refresh your knowledge about immune cells and may even offer some education or entertainment.

The recommended procedures for perioperative management in patients using novel oral anticoagulants (NOACs) stem from the requirement to minimize treatment interruption before and after surgical procedures to reduce the risk of bleeding and thromboembolism. The safety of these regimens in patients with atrial fibrillation was examined in the prospective PAUSE study presented below.

Adherence to statin therapy remains suboptimal despite its proven benefits in reducing cardiovascular risk in individuals with dyslipidemia. Recently published survey results conducted among patients prescribed statins have identified barriers preventing proper adherence to this treatment.

For such a rare hereditary disorder as alpha-1 antitrypsin deficiency (AATD), we have so far used functional tests as the main tool for monitoring the progression of lung disease. Now we are moving further. Quantitative CT examination is even more advantageous in terms of assessing clinical development.